Hims and Hers Health Inc vs Vanguard High Dividend Yield ETF — how do they compare? Hims and Hers Health Inc trades at $28.42 (market cap $6.89B), while Vanguard High Dividend Yield ETF trades at $158.56 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 14.6× Hims and Hers Health Inc's market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| HIMS | VYM | |
|---|---|---|
Market Cap | $6.89B | $100.80B |
Volume | 5,446,628 | 908,176 |
Sector | Health | — |
52-Week High | $62.76 | $167.03 |
52-Week Low | $14.52 | $137.47 |
Typical Hold Time | 21 Days | 138 Days |
Enterprise Value | $7.60B | — |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $29.54, up 0.24% on the day, with a bullish technical signal from moving averages but mixed earnings performance. Revenue grew to $2.35 billion in 2025, yet the company posted a net loss of $142 million in 2026, reflecting profitability challenges. High valuation ratios like a P/E of 57.14 and negative ROE of -32.03% indicate premium pricing despite weak earnings. Recent news highlights multiple securities class action lawsuits filed in October 2026, creating legal overhangs.
The stock faces headwinds from profitability struggles and legal risks, but analyst consensus remains a Buy with a $32.17 price target, suggesting modest upside. Investment appeal hinges on resolving operational inefficiencies and legal issues to align valuation with fundamentals, while current sentiment is cautious due to recent earnings misses and regulatory scrutiny.
VYM trades at $157.45, down 0.58% on the day, with a bearish technical signal from moving averages while oscillators remain neutral. The ETF's 2.42% yield provides consistent income, though recent articles highlight performance comparisons with peers like SCHD and IDV. Support and resistance levels cluster tightly around $157-158, indicating potential for near-term price consolidation.
The outlook remains cautious as VYM faces competitive pressure from higher-yielding alternatives and concerns about dividend sustainability in its holdings. While diversification and low costs are strengths, investors should weigh the trade-offs between yield consistency and total return potential in the current market environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →